61012-19-9CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CO)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](Cc1cnc[nH]1)NC(=O)[C@@H]1CCC(=O)N1)C(C)(C)CXJWIEWPGHRSZJM-MGZASHDBSA-NSicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Danger
H360 (100%): May damage fertility or the unborn child [Danger Reproductive toxicity]
P203, P280, P318, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory.
VerwendenMammalian LHRHa containing Supergestran was used to stimulate the spermiation of tench males. Half dose of lecirelin was almost equally effective to induce the disappearance of the dominant follicle at Day 6 to 7 of the estrous cycle in three GnRH analogs of cattle.
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Wird geladen…
61012-19-9DTXSID00735365DefinitionLecirelin, a synthetic gonadotropin-releasing hormone (GnRH) analog, acts as a GnRH agonist. Lecirelin is widely used for the research of bovine ovarian follicular cysts. lecithin and buserelin, two nonapeptides, are used as the acetate. Lecirelin differs by substitution of D-tertiary leucine for glycine at position 6 and the replacement of glycine by ethylamide at position 10. Buserelin has a D-serine at position 6 and ethylamide at position 10.